Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-05280586 versus EU- and US-sourced rituximab in active rheumatoid arthritis
2011-002896-40Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jun 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rituximab in rheumatoid arthritis (RA) (3 arms), sponsored by Pfizer. Primary endpoints: Maximum observed concentration and Area under the concentration-time curve from time zero to infinity. Started Jun 2012; status: completed.
02
Drugs
rituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2011-002896-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002896-40.